A review article on hyperlipidemia: Types, treatments and new drug targets

Biomedical and Pharmacology Journal

Volumn 7, Issue 2, 2014, Pages 399-409

  Shattat, Ghassan F ^a  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

Diacyl glycerol acyl transferase inhibitors; Hyperlipidemia; Hypolipidemic drugs; Lanosterol synthase inhibitors; Lipid metabolism; Squalene epoxidase inhibitors

Indexed keywords

ACETYL COENZYME A ACETYLTRANSFERASE; ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE INHIBITOR; ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DIACYL GLYCEROL ACYL TRANSFERASE INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE INHIBITOR; LANOSTEROL SYNTHASE INHIBITOR; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; NEW DRUG; NICOTINIC ACID; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SQUALENE EPOXIDASE INHIBITOR; SQUALENE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; BLOATING; BRAIN ISCHEMIA; CONSTIPATION; CORONARY ARTERY DISEASE; DIARRHEA; DISEASE CLASSIFICATION; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TARGETING; FLATULENCE; GALLSTONE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INDIGESTION; LIPID METABOLISM; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MYALGIA; MYOPATHY; NAUSEA; NONHUMAN; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; PROTEIN STRUCTURE; PRURITUS; REVIEW; SYMPTOM;

EID: 84923070560     PISSN: 09746242     EISSN: 24562610     Source Type: Journal    
DOI: 10.13005/bpj/504     Document Type: Review

References (57)

1. Ginghina, C., Bejan, I., Ceck, C. D. Modern risk stratification in coronary heart disease. J. Med. Life. 4(4): 377-86 (2011).
2. Jorgensen, T., Capewell, S., Prescott, E., Allender, S., Sans, S., Zdrojewski, T. Population-level changes to promote cardiovascular health. Eur. J. Prev. Cardiol., 20(3):409-21 (2013).
3. Mishra, P. R., and Panda., P. K., Apanna, K.C., Panigrahi, S. Evaluation of acute hypolipidemic activity of different plant extracts in Triton WR-1339 induced hyperlipidemia in albino rats. Pharmacologyonline., 3: 925-934 (2011).
4. Jeyabalan, S., Palayan, M. Antihyperlipidemic activity of Sapindusemarginatus in Triton WR-1339 induced albino rats. Res. J. Pharm. Tech., 2(2):319-323 (2009).
5. Brouwers, M. C., and VanGreevenbroek., M. M., Stehouwer, C. D., de Graaf, J., Stalenhoef, A. F. Thegenetics of familial combined hyperlipidaemia. Nat. Rev. Endocrinol., 8(6): 352-62 (2012).
6. Kumar, D., Parcha, V., Maithani, A., Dhulia, I. Effect and evaluation of antihyperlipidemic activity guided isolated fraction from total methanol extract of Bauhinia variegata (linn.) in Triton WR-1339 induced hyperlipidemic rats. Asian Pac. J. Trop. Dis., 2(2): 909-913 (2012).
7. thedn, USA, TheMcgraw Hill Companies, 2007; pp98-108.
8. rdedn, U.K: Blackwell Publishing Ltd, 2007; pp133-134.
9. thedn, Amsterdam: Elsevier, 2002; pp483-504.
10. Harvey, R. A., Ferrier, D. R. Cholesterol and steroid metabolism In: (Rhyner, S.), Biochemistry, 5th edn, USA: Lippincott Williams & Wilkins, 2011; pp227-237.
11. Wang, H., Eckel, R. H. Lipoprotein lipase: from gene to obesity. Am. J. Physiol. Endocrinol. Metab., 297 (2): 271-288 (2009).
12. Santamarina-Fojo, S., González-Navarro, H., Freeman, L., Wagner, E., Nong, Z. Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler. Thromb. Vasc. Biol., 24(10): 1750-1754 (2004).
13. Nakhjavani, M., Morteza, A., Karimi, R., Banihashmi, Z., Esteghamati, A. Diabetes induces gender gap on LCAT levels and activity. Life Sci., 92(1): 51-54 (2013).
14. Durrington, P. N. Cholesteryl ester transfer protein (CETP) inhibitors. Br. J. Cardiolo., 19(3):126-133 (2012).
15. Hussain, M., Rava, P., Walsh, M., Rana, M., Jahangir Iqbal, J. Multiple functions of microsomal triglyceride transfer protein. Nutr. Metab., (9):14-30 (2012).
16. Chang, T. Y., and Li., B. L., Chang, C. Y., Urano, Y. Acyl-coenzyme A: cholesterol acyltransferases. Am. J. Physiol-Endoc. M., 297(1): E1-E9 (2009).
17. McLaren J. E., Michael D. R., Ashlin T. G., Ramji D. P. Cytokines, macrophage lipid metabolism and foam cells: Implications for cardiovascular disease therapy. Prog. Lipid Res., 50(4):331-347 (2011).
18. Hegele, A. R. Plasma lipoproteins: genetic influences and clinical implications. Nat. Rev. Genet., (10): 109-121 (2009).
19. thedn, India: JP brothers medical publishers, pp613-614 (2008).
20. thedn, The McGraw Hill companies, Inc. 2011; pp370.
21. Wouters, K., Shiri-Sverdlov, R., van Gorp, P. J., van Bilsen, M., Hofker, M.H. Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice. Clin. Chem. Lab. Med., 43(5):470-9 (2005).
22. Gao, W., He, H. W, Wang, Z. M., Zhao, H., Xiao-Qing Lian, X. Q., Wang, Y. S., Zhu, J., Jian-Jun Yan, J. J., Zhang, D. G., Zhi-Jian Yang, Z. J., Wang, L. S. Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis., (11): 55 (2012).
23. Nickolas, T.L., Radhakrishnan, J., Appel, G.B. Hyperlipidemia and thrombotic complications in patients with membranous nephropathy. Semin. Nephrol.; 23(4):406-11 (2003).
24. Amarenco, P., Labreuche, J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol., 8 (5): 453-463 (2009).
25. Belay, B., and Belamarich., P. F., Tom-Revzon, C. The use of statins in pediatrics: knowledge base, limitations, and future directions. Pediatrics., 119(2): 370-380 (2006).
26. Eiland, L. S., Luttrell, P. L. Use of statins for dyslipidemia in the pediatric population. J. Pediatr. Pharmacol. Therap., 15(3): 160-172 (2010).
27. Sharma, M., Tiwari, M., Chandra, R. Bis[3-(4'-substituted phenyl)prop-2-ene]disulfides as a new class of antihyperlipidemic compounds. Bioorg. Med. Chem. Lett., 14(21); 5347-5350 (2004).
28. thedn, New York: McGraw Hill, 2001; pp971-1002.
29. Bellosta, S., Paoletti, R., Corsini, A. Atherosclerosis: Evolving vascular biology and clinical implications, safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation, (109): 50-57 (2004).
30. Mills, E. J., Wu, P., Chong, G., Ghement, I., Singh, S., Akl. E. A., Eyawo, O., Guyatt, G., Berwanger, O., Briel, M. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM, 104(2):109-124 (2011).
31. Russell, D. W. The enzymes, regulation, and genetics of bile acid synthesis, Annu. Rev. Bioch., (72): 137-174 (2003).
32. Kishor, S., Kathiravan, M., Somani, R., Shishoo, C.H. The biology and chemistry of hyperlipidemia. Bioorg. Med. Chem., 15(14): 4674-4699 (2007).
33. Arnold, M.A., Swanson, B.J., Crowder, C.D., Frankel, W.L., Lam-Himlin, D., Singhi, A.D., Stanich, P.P., Arnold, C.A. Colesevelam and colestipol: novel medication resins in the gastrointestinal tract. Am. J. Surg. Pathol.; 38(11):1530-7 (2014).
34. Safeer, R. S., Lacivita, C.L. Choosing drug therapy for patients with hyperlipidemia. Am. Fam. physician, 61(11): 3371-82 (2000).
35. Fruchart, J-C., Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 98(19): 2088-2093 (1998).
36. Martin, G., Schoonjans, K., Lefebvre, A., Staels, B., Auwerx, J. Coordinate regulation of the expression of the fatty acid transporter protein (FATP) and acyl CoA synthetase (ACS) genes by PPARá and PPARã activators. J. Biol. Chem., 272: 28210-28217 (1997).
37. Caslake, M., Packard, C., Gaw, E., Murray, E., Griffin, B., Vallance, B., Shepherd, J. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol., (13): 702-711 (1993).
38. Berthou, L., Duverger, N., Emmanuel, F., Langouët, S., Auwerx, J., Guillouzo, A., Fruchart, J-C., Rubin, E., Dene'fle, P., Staels, B., Branellec, D. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apo A-I transgenic mice. J. Clin. Invest., 97(11): 2408-2416 (1996).
39. Carlson, L.A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med., 258(2):94-114 (2005).
40. Nutescu, E. A., Shapiro, N. L. Ezetimibe: a selective cholesterol absorption inhibitor. Pharmacotherapy., 23(11): 1463-74 (2003).
41. Denke, M., Pearson, T., McBride, P. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab. Vasc. Dis. Res., 3(2): 93-102 (2006).
42. Altmann, S. W., and Davis., H. R., Zhu, L. J. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science, 303 (5661): 1201-1204 (2004).
43. Pattis, P., Wiedermann, C. J. Ezetimibe-associated immune thrombocytopenia. Ann. Pharmacother., 42(3): 430-433 (2008).
44. Llaverías, G., and Laguna., J. C., Alegret, M. Pharmacology of the ACAT inhibitor avasimibe (CI-1011). Cardiovasc. Drug Rev., 21(1): 33-50 (2003).
45. López-Farré, A. J., Sacristán, D., Zamorano-León, J. J., San-Martín, N., Macaya, C. Inhibition of acyl-CoA cholesterol acyltransferase by F12511 (Eflucimibe): Could it be a new antiatherosclerotic therapeutic? Cardiovasc. Ther., 26(1): 65-74 (2008).
46. Lee, k., and Cho., S. C., Lee, J. H., Goo, J., Lee, S. Y., and Boovanahalli., S. K., Koon, S., Yeo, Y. C., Lee, S-J., Kim, Y. K., Kim, D. H., Choi, Y., Song, G.-Y. Synthesis of a novel series of 2-alkylthio substituted naphthoquinones as potent acyl-CoA: Cholesterol acyltransferase (ACAT) inhibitors. Europ. J. Med. Chem., 62: 515-525 (2013).
47. Magnin, D. R., and Biller., S. A., Wetterau, J., Robl, J. A., Dickson, J. K. Jr., Taunk, P., Harrity, T. W., Lawrence, R. M., Sun, C.Q., Wang, T., Logan, J., Fryszman, O., Connolly, F., Jolibois, K., Kunselman, L. Microsomal triglyceride transfer protein inhibitors: discovery and synthesis of alkyl phosphonates as potent MTP inhibitors and cholesterol lowering agents. Bioorg. Med. Chem. Lett., 13(7): 1337-1340 (2003).
48. Goldberg, A. S., Hegele, R. A. Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib. Druges. Devel. Ther., 6: 251-259 (2012).
49. Shinkai, H. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Vasc. Health risk Manag., (8): 323-331 (2012).
50. Liu, C.-I., Jeng, W.-Y., Chang, W.-J., Ko, T.-P., Andrew Wang, A. H.-J. Binding modes of zaragozic acid A to human squalene synthase and staphylococcal dehydrosqualene synthase. J. Biol. Chem., 287(22): 18750-18757 (2012).
51. Sharma, A., and Slugg., P. H., Hammett, J. L., Jusko, W. J. Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. J. Clin. Pharmacol., 38(12): 1116-1121 (1998).
52. Ugawa, T., Kakuta, H., Moritani, H., Matsuda, K., Ishihara, T., Yamaguchi, M., Naganuma, S., Iizumi, Y., Shikama, H. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br. J. Pharmacol., 131(1): 63-70 (2000).
53. Ma, Z., Chu, C.-H., Cheng, D. A novel direct homogeneous assay for ATP citrate lyase. J. Lipid Res., 50(10): 2131-2135 (2009).
54. Li, J. J., Wang, H., Tino, J. A., and Robl., J. A., Herpin, T. F., Lawrence, R. M., Biller, S., Jamil, H., Ponticiello, R., Chen, L. 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors, Bioorg. Med. Chem. Lett., 17(11): 3208-3211 (2007).
55. Cao, J., Zhou, Y., Peng, H., Huang, X., Stahler, S., Suri, V., Qadri, A., Gareski, T., Jones, J., Hahm, S., Perreault, M., McKew, J., Shi, M., Xu, X., Tobin, J. F., Gimeno, R. E. Targeting Acyl-CoA: diacylglycerolacyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. J. Biol. Chem., 286(48): 41838-41851 (2011).
56. Horie, M., Sawasaki, Y., Fukuzumi, H., Watanable, K., Lizuka, Y., Tsuchiya, Y., Kamei, T. Hypolipidemic effects of NB-598 in dogs. Atherosclerosis, 88(2-3): 183-192 (1991).
57. Rozman, D., Monostory, K. Perspectives of the non-statin hypolipidemic agents. Pharmacol. Ther., 127(1): 19-40 (2010).